Immunovia AB Statistics

Total Valuation

Immunovia AB has a market cap or net worth of SEK 194.36 million. The enterprise value is 165.56 million.

Market Cap	194.36M
Enterprise Value	165.56M

Important Dates

The last earnings date was Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunovia AB has 306.08 million shares outstanding. The number of shares has increased by 330.27% in one year.

Current Share Class	306.08M
Shares Outstanding	306.08M
Shares Change (YoY)	+330.27%
Shares Change (QoQ)	+23.37%
Owned by Insiders (%)	6.89%
Owned by Institutions (%)	14.07%
Float	284.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	211.49
PB Ratio	10.95
P/TBV Ratio	11.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.13
EV / Sales	180.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.03.

Current Ratio	1.91
Quick Ratio	1.91
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1.63

Financial Efficiency

Return on equity (ROE) is -784.16% and return on invested capital (ROIC) is -269.43%.

Return on Equity (ROE)	-784.16%
Return on Assets (ROA)	-134.91%
Return on Invested Capital (ROIC)	-269.43%
Return on Capital Employed (ROCE)	-566.40%
Revenue Per Employee	114,875
Profits Per Employee	-18.36M
Employee Count	9
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.24% in the last 52 weeks. The beta is 2.62, so Immunovia AB's price volatility has been higher than the market average.

Beta (5Y)	2.62
52-Week Price Change	-17.24%
50-Day Moving Average	0.59
200-Day Moving Average	0.48
Relative Strength Index (RSI)	47.94
Average Volume (20 Days)	14,803,232

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Immunovia AB had revenue of SEK 919,000 and -146.84 million in losses. Loss per share was -0.76.

Revenue	919,000
Gross Profit	919,000
Operating Income	-100.50M
Pretax Income	-146.84M
Net Income	-146.84M
EBITDA	-90.12M
EBIT	-100.50M
Loss Per Share	-0.76

Full Income Statement

Balance Sheet

The company has 29.27 million in cash and 467,000 in debt, giving a net cash position of 28.80 million or 0.09 per share.

Cash & Cash Equivalents	29.27M
Total Debt	467,000
Net Cash	28.80M
Net Cash Per Share	0.09
Equity (Book Value)	17.74M
Book Value Per Share	0.06
Working Capital	15.49M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-88.13M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-10,935.47%
Pretax Margin	-15,978.35%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovia AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-330.27%
Shareholder Yield	n/a
Earnings Yield	-75.55%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunovia AB has an Altman Z-Score of -54.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-54.98
Piotroski F-Score	4